Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD …
Full MYNZ analysis →
Competitive advantage assessment
Key strengths
Elite Gross MarginsGross margin quality is top-tier vs peers (score 0.75). This signals strong consumable attach-rate economics.
Mainz Biomed N.V. ranks #43 of 62
scored companies in Diagnostics & Research by moat score — the top 69%.
The widest moat in the group is IDEXX Laboratories, Inc. (IDXX)
at 78/100.
Moat scores for companies ranked near MYNZ in Diagnostics & Research
How MYNZ scores on the Medical Devices & Diagnostics defenses
Pricing Power & Consumable Moat
Score 54
· 25% of the moat score
In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.
R&D Pipeline & Capital Returns
Score 12
· 20% of the moat score
Research spending is how a device company keeps its installed base current, but spending alone proves nothing.
FCF Quality & Cash Conversion
Score 47
· 20% of the moat score
MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.
Commercial Execution
Score 42
· 15% of the moat score
Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.
Capital Structure & Resilience
Score 32
· 12% of the moat score
Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.
Growth Durability
Score 18
· 8% of the moat score
Growth durability separates an expanding installed base from a good product cycle.
Mainz Biomed N.V. (MYNZ) scores 37 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #43 of 62 scored companies in Diagnostics & Research, the top 69%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 61 companies in Diagnostics & Research. Its strongest defense is Pricing Power & Consumable Moat (54/100) and its weakest is R&D Pipeline & Capital Returns (12/100).
How does Mainz Biomed N.V. compare with other Diagnostics & Research companies?
Mainz Biomed N.V. ranks #43 of 62 scored companies in Diagnostics & Research by moat score. The widest moat in Diagnostics & Research is IDEXX Laboratories, Inc. (IDXX) at 78/100. The companies ranked closest are Fulgent Genetics, Inc. (FLGT) at 42 just above it and Inotiv, Inc. (NOTV) at 37 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 61 companies in Diagnostics & Research. The defenses are then weighted to produce the overall score out of 100.
Why is Mainz Biomed N.V. scored with the Medical Devices & Diagnostics template?
Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.
Which competitive defenses are measured for Mainz Biomed N.V.?
The Medical Devices & Diagnostics template measures 6 defenses, and MYNZ scores: Pricing Power & Consumable Moat (54), R&D Pipeline & Capital Returns (12), FCF Quality & Cash Conversion (47), Commercial Execution (42), Capital Structure & Resilience (32), Growth Durability (18). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.